Related Experiment Video
Updated: Aug 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Factors relevant to preventing embolic stroke in patients with non-rheumatic atrial fibrillation
K M Flegel1, T A Hutchinson, P A Groome
1Department of Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
Insights
Anticoagulant therapy offers benefits for most patients with non-rheumatic atrial fibrillation, preventing embolic stroke. Individual patient preferences for avoiding stroke versus bleeding risks significantly influence treatment decisions.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Physicians face a dilemma regarding anticoagulant use in non-rheumatic atrial fibrillation to prevent embolic stroke.
- Ongoing randomized trials may not fully resolve treatment decisions due to unaddressed patient-specific factors.
Purpose of the Study:
- To determine the overall benefit of anticoagulants in non-rheumatic atrial fibrillation.
- To identify crucial factors influencing anticoagulant therapy decisions beyond randomized trial parameters.
Main Methods:
- Utilized existing knowledge of non-rheumatic atrial fibrillation.
- Employed a method to elicit patient-derived weights for stroke avoidance versus bleeding risk.
- Analyzed benefits using standard assumptions and sensitivity analyses for various clinical parameters.
Main Results:
- Anticoagulants demonstrated an expected benefit for all subjects, ranging from 5.4 to 46.7 lives saved per 1000 patients.
- Benefit persisted across sensitivity analyses for stroke prevention and intracranial hemorrhage rates.
- Benefit diminished for some subjects when considering different baseline stroke rates and major bleeding impacts.
Conclusions:
- Crucial decision-making factors, such as patient-valued trade-offs between stroke and bleeding, are not typically measured in randomized trials.
- Individualized assessment of patient preferences is paramount in determining the net benefit of anticoagulation.
- Anticoagulant therapy is likely beneficial for most patients with non-rheumatic atrial fibrillation.
Abstract:
Whether or not to treat patients with non-rheumatic atrial fibrillation with anticoagulants to prevent embolic stroke is a dilemma for physicians. If randomized trials, currently underway, demonstrate a beneficial effect, the dilemma will not be solved because not all of the relevant factors can be addressed by trials. We used current knowledge about non-rheumatic atrial fibrillation and a method of obtaining patient-derived weights for avoiding stroke from eight medically trained subjects, to determine the overall benefit of anticoagulants and to see what factors were relevant and what effect each might have in deciding whether to use anticoagulant therapy. Using standard assumptions, anticoagulants gave an expected benefit for all subjects. The expected benefit (expressed in terms of lives per 1000 saved due to anticoagulants) varied between 5.4 and 46.7. This benefit remained for all subjects when we did a sensitivity analysis for different rates of stroke prevented by anticoagulants and different rates of intracranial hemorrhage caused by anticoagulants. When we used different baseline rates of stroke and different impacts of major hemorrhagic complications the benefit disappeared for 3 and 4 subjects respectively. We found the factors that were most crucial to the decision will not be included in randomized trials; the weight that an individual would place on avoiding embolic stroke vs the risk of intracranial bleeding from anticoagulant therapy; and the rate of embolic stroke that could be expected for the subject at risk. Factors which will be measured in randomized trials, will change results less substantially: the increased risk of major hemorrhages; the proportion of strokes that could be prevented by treatment; the increase in risk of intracranial hemorrhage. This method of analysis suggests that for most patients anticoagulants are beneficial and that the most important factor in determining this result is the value that subjects put on different outcomes.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management

